Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
fda
life sciences
national blog main
patisiran
4
×
akcea therapeutics
clinical trials
drugs
hereditary transthyretin amyloidosis
inotersen
national top stories
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
pfizer
san francisco blog main
san francisco top stories
vyndaqel
acute hepatic porphyrias
akin akinc
aminolevulinic acid
andrew fire
barry greene
biotech
boston university
craig mello
dan ollendorf
european medicines agency
givosiran
harvard pilgrim health care
institute for clinical and economic review
john berk
john maraganore
What
alnylam
fda
medicine
4
×
drug
rna
rnai
ago
interference
pharmaceuticals
uses
afternoon
alnylam’s
approval
approve
approved
approves
awaits
biological
cells
crossed
decades
decision
discovered
ema
employ
europe
fingers
follows
friday
gene
gets
harmful
historic
history
hits
indicated
landmark
make
making
method
Language
Current search:
patisiran
×
medicine
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision